New York-based precision medicine startup Celmatix has raised $5.5 million, according to a regulatory filing, bringing its total funding to date to about $13 million. The money was provided by private equity firm Topspin Partners, as well as a number of angel investors.

Celmatix is using predictive modeling that involves big data- and genomics-driven approach to help women “optimize” their fertility. The company’s lead product, Polaris, calculates a woman’s likelihood of success using different fertility treatment options. Its web-based modeling generates a side-by-side comparison of a patient’s likelihood to conceive with timed intercourse, non-IVF and IVF. Next year, it will launch Polaris X, a companion genetic diagnostic for the Polaris platform that shows subclinical factors that impact fertility.

According to Celmatix researchers, 25 percent of IVF patients discontinue treatment even though they still have a good chance of conceiving. In addition, researchers have also found that mutations that lead to degeneration of egg quality are the main reason that IVF fails.

Celmatix has a number of partnerships in place – such as with Washington University in St. Louis, University of Connecticut and a number of reproductive medicine clinics in Michigan, Pennsylvania and New York.

In the U.S. alone, 6.7 million women have difficulty getting pregnant, according to the CDC.

[Via: MedCityNews]